AnaptysBio reported earnings of $ 0.11 per ANAB share on Nov 12, 2026, falling short of analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 1.84 |
| Earnings Per Share (Surprise) | $ 0.11 (+$ 1.95) |
| Last Year's EPS | -$ 0.13 |
| EPS YoY Change |
Out of the last 51 earnings reporting periods, AnaptysBio beat analysts’ expectations 24 times and fell short of expectations 14 time(s). AnaptysBio reported earnings per share of $ 0.11 in the last report surpassing an estimated EPS of -$ 1.84 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 1.84 | $ 0.11 | $ 0.52 | |
| Sep 21, 2026 | $ 5.11 | $ 5.11 | -$ 1.34 | |
| May 12, 2026 | -$ 0.32 | -$ 1.84 | -$ 1.28 | |
| Mar 3, 2026 | $ 0.89 | $ 1.58 | -$ 0.72 | |
| Nov 4, 2025 | -$ 1.06 | $ 0.52 | -$ 1.14 | |
| Aug 7, 2025 | -$ 1.50 | -$ 1.34 | -$ 1.71 | |
| May 5, 2025 | -$ 1.30 | -$ 1.28 | -$ 1.64 | |
| Feb 27, 2025 | -$ 1.55 | -$ 0.72 | -$ 1.59 | |
| Nov 5, 2024 | -$ 1.65 | -$ 1.14 | -$ 1.41 | |
| Aug 5, 2024 | -$ 0.99 | -$ 1.71 | -$ 1.50 | |
| May 9, 2024 | -$ 1.57 | -$ 1.64 | -$ 1.58 | |
| Mar 12, 2024 | -$ 1.60 | -$ 1.59 | -$ 0.93 | |
| Nov 2, 2023 | -$ 1.79 | -$ 1.41 | -$ 1.18 | |
| Aug 7, 2023 | -$ 1.70 | -$ 1.50 | -$ 1.15 | |
| May 11, 2023 | -$ 1.05 | -$ 1.58 | -$ 1.31 | |
| Mar 1, 2023 | -$ 0.96 | -$ 0.93 | -$ 1.13 | |
| Nov 8, 2022 | -$ 0.72 | -$ 1.18 | -$ 0.24 | |
| Aug 8, 2022 | -$ 1.02 | -$ 1.15 | -$ 0.02 | |
| May 4, 2022 | -$ 0.99 | -$ 1.31 | -$ 0.66 | |
| Mar 7, 2022 | $ 2.57 | -$ 1.13 | $ 1.20 |
AnaptysBio’s stock was trading at $ 48.77 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, ANAB’s price decreased to $ 46.25 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | $ 0.11 | $ 48.77 | $ 46.25 | |
| Sep 21, 2026 | $ 5.11 | $ 55.20 | $ 53.92 | |
| May 12, 2026 | -$ 1.84 | $ 67.92 | $ 62.69 | |
| Mar 3, 2026 | $ 1.58 | $ 36.61 | $ 40.37 | |
| Nov 4, 2025 | $ 0.52 | $ 24.03 | $ 24.00 | |
| Aug 7, 2025 | -$ 1.34 | $ 15.03 | $ 14.02 | |
| May 5, 2025 | -$ 1.28 | $ 14.13 | $ 13.41 | |
| Feb 27, 2025 | -$ 0.72 | $ 11.33 | $ 11.21 | |
| Nov 5, 2024 | -$ 1.14 | $ 13.29 | $ 14.81 | |
| Aug 5, 2024 | -$ 1.71 | $ 21.84 | $ 21.39 | |
| May 9, 2024 | -$ 1.64 | $ 17.17 | $ 15.61 | |
| Mar 12, 2024 | -$ 1.59 | $ 15.57 | $ 16.46 | |
| Nov 2, 2023 | -$ 1.41 | $ 11.03 | $ 11.69 | |
| Aug 7, 2023 | -$ 1.50 | $ 12.47 | $ 12.63 | |
| May 11, 2023 | -$ 1.58 | $ 14.32 | $ 12.97 | |
| Mar 1, 2023 | -$ 0.93 | $ 16.60 | $ 16.36 | |
| Nov 8, 2022 | -$ 1.18 | $ 19.39 | $ 19.53 | |
| Aug 8, 2022 | -$ 1.15 | $ 16.46 | $ 15.43 | |
| May 4, 2022 | -$ 1.31 | $ 16.31 | $ 14.42 | |
| Mar 7, 2022 | -$ 1.13 | $ 20.17 | $ 19.45 |
AnaptysBio released its most recent earnings reports in November 2026, September 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
AnaptysBio beat analysts’ expectations during the last earnings period by
